Skip to content

Sodium phosphate

ALIMENTARY TRACT AND METABOLISM

Also known as: disodium phosphate, sodium phosphate, dibasic, sodium phosphate, dibasic anhydrous, sodium phosphate, dibasic, heptahydrate, sodium phosphate, monobasic anhydrous, sodium phosphate, monobasic, anhydrous

FDA approvedATC A06AD17ATC A06AG01ATC B05XA09

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Sodium phosphate is a drug catalogued in DrugCentral. It was first approved by the FDA in 1983. DrugCentral lists 1 molecular target, including CA4. Recorded indications include Constipation.

  • Molecular targets: CA4 (1 listed in DrugCentral).
  • Indications: Constipation.
  • ATC code: A06AD17 (Osmotically acting laxatives).
  • Molecular formula: HNa2O4P; molecular weight 141.96 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Constipation

Mechanism & targets

Molecular targets (1)

TargetGeneActionActivity
Carbonic anhydrase 4CA4unknownKi 5.01

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
1983-05-10FDA—HOSPIRA

ATC classification

ATC codeTherapeutic hierarchy
A06AD17ALIMENTARY TRACT AND METABOLISM › DRUGS FOR CONSTIPATION › DRUGS FOR CONSTIPATION › Osmotically acting laxatives
A06AG01ALIMENTARY TRACT AND METABOLISM › DRUGS FOR CONSTIPATION › DRUGS FOR CONSTIPATION › Enemas
B05XA09BLOOD AND BLOOD FORMING ORGANS › BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS › I.V. SOLUTION ADDITIVES › Electrolyte solutions
V03AG05VARIOUS › ALL OTHER THERAPEUTIC PRODUCTS › ALL OTHER THERAPEUTIC PRODUCTS › Drugs for treatment of hypercalcemia

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Appendicolith277.6
Appendicitis212.2
Cardiogenic shock166.2
Blood phosphorus increased165.1
Ventricular fibrillation145.6
Hyperphosphataemia145.3
Hypophosphataemia126.5
Ascites125.9
Blood uric acid increased125.1
Aplastic anaemia122.9
Myasthenia gravis122.7
Abdominal distension114.3

Chemical structure

Molecular formulaHNa2O4P
Molecular weight141.96 g/mol
CAS number7558-79-4
InChIKey—
PubChem CID24243

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Sodium phosphate used for?

DrugCentral lists the following indications for Sodium phosphate: Constipation.

How does Sodium phosphate work?

Its molecular targets in DrugCentral include CA4.

When was Sodium phosphate first approved?

Sodium phosphate was first approved by the FDA in 1983.

What is the chemical formula of Sodium phosphate?

Sodium phosphate has the molecular formula HNa2O4P and a molecular weight of 141.96 g/mol.

Browse: all drugs starting with S · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

Status—
First approval1983-05-10
AgencyFDA
Targets1
Indications1
FormulaHNa2O4P
DrugCentral ID4219
Interactive profile